

Index

- abandonment category, real options 129, 132–9
abbreviated new drug applications (ANDAs) 62–3
 see also generic drugs
absorption characteristics, ADMET 44–5, 47, 55
Absorption, Distribution, Metabolism, Excretion
 and Toxicology (ADMET) 44–7, 54–5
ABT-874 86–92
Access to Life Saving Medicines Act 157–8
accounting models, valuation 27
accounting period, definition 13
accounting policies 15–16, 26
accounts payable
 see also creditors
 concepts 18, 19–20, 21–2, 23–4
 definition 19
accounts receivable
 concepts 18–20, 21–2, 23–4
 definition 18
accruals concept, definition 13
accrued expenses
 concepts 20, 23–4
 definition 20
accumulated depreciation, definition 19, 23–4
Actelion 94, 100–4
Adderall XR 98–9
additional paid-in capital (APIC) 20
ADHD 61
ADMET *see* Absorption, Distribution,
 Metabolism, Excretion and Toxicology
advisory committees, US 60–3, 146–7
affiliates, investments 19
ageing populations 41, 145
agriculture 7–8
AiM 2
Alzheimer's disease 54, 145
AMEX 2, 125, 143
Amgen Inc. 86, 103, 145, 147, 157
amortization
 cash flow statements 21–2
 concepts 14–17, 21–2, 26, 30, 37
 definition 14–15
 goodwill 19
analysis 1–4, 7–8, 39–40, 41–2, 45–7, 56–9,
 61–2, 67, 71–83, 141–60
 guidelines 56–9, 61–2, 66, 73–4, 141–60
 information sources 2–3, 4, 7–8, 39–40, 41–2,
 56–9, 71–83, 145–53, 158–9
 roles 1–2
 subjective/objective assessments 2–3, 11,
 28–30, 69–70, 119–20, 141–60
ANDAs *see* abbreviated new drug applications
animal studies, preclinical development 42–7,
 73–4, 121–39
Antegren 110–15
APIC *see* additional paid-in capital
approvable/approved issues 61–2, 65, 126, 146,
 154, 157
Arpida 94
'art' factors, valuation 2–4, 11, 37, 69–70, 119
arthritis 54, 77–8, 134–5, 145
Asia-Pacific, biotechnology statistics 7
assets
 see also biotechnology assets; current...; fixed...
 balance sheets 13, 17–24
 concepts 17–20, 23–4, 73–118, 160
 definition 18
 drug assets 73–118, 160
 historic cost method 20
 types 18–19
asthma 54, 77–8
AstraZeneca 86–92, 94, 100–4
attrition rates 51–4, 74, 106
Avastin 76–7
Avonex 110–16, 118

'back of the envelope' calculations 91–2
balance sheets
 analysis 11–12, 17–20
 book value 26–7
 cash 18–20, 22–4, 155

- balance sheets (*Continued*)
cash flow statements 24
concepts 11–12, 13, 17–20, 22–4, 66
definition 13, 17
equation 17, 20
income statements 21, 23
layout example 18, 23–4
multiples 26–8, 99–104
'ballpark' valuations 168
bank debt 20
BASF AG 103
Basilea Pharmaceutica 49, 94
Bayer AG 103
Bayh-Dole Act 143
benchmarking
 see also comparable company analysis
 benefits 71–2
beta
 concepts 33–7, 93–104, 124–5, 166–8
 definitions 33, 93, 95
Betaseron 112–16
bibliography 4
binomial lattices
 concepts 119–20, 127–8, 129–39
 definition 129–30
BIO *see* Biotechnology Industry Organization
bioavailability, definition 46
BioCentury 157
BioDream 132–9
Biogen Idec Inc. 103, 110
BioPartners 157
biosimilar compounds, state of play 106, 116–18
biotechnology
 see also companies; drug development; R&D;
 valuation
 1976–1985 period 147
 1986–1992 period 147
 1992–2000 period 2–3, 144, 147–8, 156
 2000 boom 2–3, 144, 147–8, 156
 background 5–10, 70–1, 141–60
 business models 1–2, 6–7, 69–70, 152–3
 concepts 1–10, 39–67, 141–60
 cycles 2–3, 142, 144, 145–52
 definition 5–6
 early-stage biotechnology companies 4, 5–6,
 11–12, 15, 33–4, 70–1, 99–101, 143–4,
 161–73
 follow-on financing 147–9, 157
 historical aspects 5–7, 143–59
 investing guidelines 56–9, 61–2, 66, 73–4,
 141–60
 IPOs 70–1, 143–4, 148–52, 158–9, 162,
 168–70, 172
 lessons 141–2, 160
 losses 7, 70–1, 76–7, 79–80, 141–3, 144–5,
 149–52, 158–9
 M&As 143–5, 146–7, 151–3, 160, 162
 management quality 11–12, 69–70, 97, 128–9,
 145–6, 154–5, 160
 partnerships 7–10, 15–16, 57–8, 74–5, 83–6,
 143–60
 pharmaceutical contrasts 6–7
 regulations 3, 4, 8–10, 39, 41–2, 47, 56, 59–66,
 143–4
 sector evolution 143–59
 statistics 7, 40–4, 70–1, 141–59, 162–5
 underperformance trends 141–3, 149–52
 VCs 1, 4, 12, 72, 148–53, 161–73
biotechnology assets, types 3–4
Biotechnology Industry Organization (BIO) 117
Biovail 160
'Bioworld dollars' 83–4
black boxes 62, 65
Black-Scholes equation 119–20, 127–8, 129–30,
134–9
blinding, clinical-trials 49–50, 58
blockbuster drugs 76–83, 106, 118, 160
Bloomberg 33–4
Blue Sky Therapeutics 73–4
boards of directors 154–5, 162
bolus injections 47
bonds 11, 16–17, 20
book value, concepts 26–7
boom of 2000 2–3, 144, 147–8, 156
bottom-up approaches, quick market models
77–82
Boyer, Herbert 5
British Biotechnology PLC 143, 154
brokerage houses 1–2
buccal administration 47
budget allocations, R&D 42–3, 144
Buffett, Warren 70
'burn rate', cash 155
Burrill & Co. 40–1
business cycles 2, 142, 145–52
business models 1–2, 6–7, 69–70, 152–3
business plans 4
buyers 1–10
call options 126–39
 see also real options
Cambridge Antibody Technology (CAT) 86–92
Canada, biotechnology statistics 7
cancer 54, 58–60, 77–80, 154–5
capital asset pricing model (CAPM), concepts
32–4, 82–3, 93–104, 124–5, 166–8
capital expenditure (capex) 21–2
capital markets *see* markets
capital structure
 valuation determinants 11–12, 30–4
 WACC 30–4, 36–7, 93–4, 124–5, 166–8
CAPM *see* capital asset pricing model

- carcinogenicity studies 47
 - see also* toxicology...
- cash
 - balance sheets 18–20, 22–4, 155
 - 'burn rate' 155
 - earnings 15–17
- cash flow statements
 - balance sheets 24
 - concepts 13, 20–2, 24
 - definition 13, 20–1
 - layout example 21, 24
 - sections 21–2, 24
- cash per share, concepts 27
- Celera 144
- cell culture facilities, costs 93
- CeNeS 57, 106–7
- centralized procedures, Europe 63–4
- Centre for Medicines Research (CMR) 42, 76
- CEOs 154–5
- chance nodes, concepts 120–3
- Chapter 20 listing rules 143
- Charles Schwab Company 82
- CHMP 60–1, 157
- cholesterol levels 59, 77–8
- chronic diseases 41–2, 145–6
- Cimzia 66–7
- Clinical Trial Certificates (CTCs) 48
- Clinical Trial Exemption applications (CTXs) 48
- clinical-trials 2, 4, 8–10, 12, 39–44, 46, 48–67, 69–70, 73–92, 106, 120–39, 146–7, 155–6, 160, 169–73
 - attrition rates 51–4, 74, 106
 - blinding 49–50, 58
 - compliance issues 51
 - concepts 39–44, 48–67, 73–4
 - control groups 42–67
 - costs 41–4, 48, 55–6, 59, 66, 93, 169–73
 - critique 59
 - delays 12
 - design issues 39, 47, 48–67
 - double-blind studies 49–50, 58
 - Europe 48, 49, 57, 63–4
 - Good Clinical Practice 48, 50
 - information sources 40, 56–9
 - intent-to-treat analysis 51, 58
 - interim study analysis 50–1
 - investor analysis guidelines 56–9, 61–2, 66, 73–4, 141–60
 - number of subjects 49–50, 55–6
 - 'per protocol' analysis 51, 58
 - phases 42, 51–6, 57–9, 60–3, 64–5, 73–4, 76, 86–92, 120–39, 155–6, 160, 169–73
 - pipeline assessments 4, 46, 66, 69–70, 73–92, 106, 146–7, 155–6, 167–8
 - placebo controls 49–50, 55
 - 'Prevention, Randomized, Double-Blind, Placebo Control' design summary 49–50
 - probabilities of success/attrition 51–5, 74, 93, 106, 122–39
 - regulations 41–3, 47, 48, 49–50, 56, 59–66, 146–53
 - risk 49–50, 51–4, 60–1
 - safety issues 49–50, 51–4, 60–6, 146–7
 - selection of subjects 49
 - standards 48
 - study analysis 48, 50–1, 56–59
 - study conduct 48, 50
 - study design 48, 49–50
 - study endpoints 50
 - study objective 48–9, 56, 58
 - study report 48, 51, 56–9, 60–3
 - success rates 51–4, 93, 122–39
 - surrogate markers 59
 - timelines 40, 41–4, 53, 65–6, 74–5, 121–39
 - UK 48
 - US 48, 49, 58, 60–3, 145–53
 - web resources 40
- CMR *see* Centre for Medicines Research
- COGS *see* cost of goods sold
- Cohen, Stanley 5
- commercial risk 7–10, 92–3, 132–3, 153, 156–9
 - see also* competitors; market...
 - concepts 7–10, 92–3, 132–3, 153, 156–9
 - decision trees 9
 - definition 8
- commercialization timelines, drug development 46, 47, 66, 125–6, 153
- Committee for Proprietary Medicinal Products (CPMP) 63–4
- common size analysis, concepts 15–17
- common stock
 - see also* share...
 - concepts 18, 20, 21–2
 - definition 20
- companies 1–10, 11–37, 69–118, 141–60, 161–73
 - see also* private...; public...; valuation
 - biotechnology statistics 7, 40–4, 70–1, 141–59, 162–5
 - boards of directors 154–5, 162
 - business models 1–2, 6–7, 69–70, 152–3
 - CEOs 154–5
 - comparable company analysis 4, 11, 15–17, 22–6, 71–2, 99–104, 162, 168–70
 - discounted stocks 142–3, 168
 - early-stage biotechnology companies 4, 5–6, 11–12, 15, 33–4, 70–1, 99–101, 143–4, 161–73
 - follow-on financing 147–9, 157
 - historical background 143–4
 - information sources 2–3, 4, 39–40, 41–2, 56–9, 71–83, 158–9

- companies (*Continued*)
 IPOs 70–1, 143–4, 148–52, 158–9, 162, 168–70, 172
 M&As 143–5, 146–7, 151–3, 160, 162
 management quality 11–12, 69–70, 97, 128–9, 145–6, 154–5, 160
 news flows 2–3, 7–8, 41–2, 56–9, 61–2, 74–5, 106–7, 142–3, 145–53, 158–9
 scandals 154–5
 types 4, 6–7
 underperformance trends 141–3, 149–52
 VCs 1, 4, 12, 72, 148–53, 161–73
comparable company analysis 4, 11, 15–17, 22–6, 71–2, 99–104, 162, 168–70
 see also relative valuation
 concepts 99–104
 early-stage biotechnology companies 162, 168–70
 methods 99–101, 168–70
 multiples 99–104
competitive advantages 160
competitors, commercial risk 8–10, 156–9
compliance issues, clinical-trials 51
conflicts of interest 1–2
consistent valuation methodologies 3–4
Consumer Health Care (CHC) 102–5
contingent claim analysis, options 127–8
contingent claims on shares
 see also convertible securities; stock options; warrants
 definition 16
 types 16–17
continuation real option 129, 132–9
control groups, clinical-trials 49–67
convertible securities 11, 16–17
Copaxone 112–16
cost of capital 22, 93–6, 124–5
cost of debt, concepts 31–4, 93–6, 166–8
cost of equity, concepts 32–4, 37, 93–6, 124–5, 166–8
cost of goods sold (COGS)
 concepts 13–17
 definition 13–14
costs
 see also expenses
 cell culture facilities 93
 clinical-trials 41–4, 48, 55–6, 59, 66, 93, 169–73
 definition 41
 drug development 40–4, 48, 55–6, 59, 66, 93
 drug discovery 40–4
 opportunity costs 30–1, 40–1
 preclinical development 45
covariance 33
CPMP *see* Committee for Proprietary Medicinal Products
creditors 18, 19–24, 31–4
 see also accounts payable
Crohn's disease 60–1, 66–7, 90–2, 108–9
Crystal Ball 126, 136
CTCs *see* Clinical Trial Certificates
CTXs *see* Clinical Trial Exemption applications
current assets
 see also assets
 concepts 18–20, 21–2, 23–4
 definition 18
current liabilities
 concepts 18, 19–20, 21–2, 23–4
 definition 19
Cymbalta 76–7
Cystic Fibrosis Foundation 161
data collation 71–33
 see also information sources
'days of therapy' 78
DCF *see* discounted cash flow analysis
deals 7–8
'Dear Doctor' letters 66
debt finance 11–12, 15–17, 20, 22, 26, 29–37, 92–5, 124–5, 155, 166–8
 see also bonds
 FCFF DCF model 29–37, 92–104
 WACC 30–4, 36–7, 92–4, 124–5, 166–8
debt to equity ratio 31–4
debtors 18–20, 21–4
 see also accounts receivable
debts
 see also creditors
 concepts 18, 19–20, 25, 31–4
 EV 26
decision nodes, concepts 120–3
decision trees 4, 8–9, 69, 119–39
 see also real options
 commercial risk 9
 concepts 8–9, 119–39
 critique 125–6
 definition 119–20
 examples 121–4, 126
 graphical aspects 120–1
 mathematical aspects 120–1
 node types 120–3
 scenario analysis 125–6
 technical risk 8–9, 125–6
 timelines 120–3
 uses 119–20
defensive medicine 145
depreciation
 accumulated depreciation 19, 23–4
 cash flow statements 21–2
 concepts 14–17, 19, 21–2, 23–4, 26, 30, 37
 definition 14
depression 77–8

- design issues, clinical-trials 39, 47, 48–67
diabetes 54, 78–9, 145
Diamond v. Chakrabarty 143
diluted EPS
 concepts 16–17, 156
 definition 16
Direct To Consumer (DTC) 145
discount rates
 CAPM 32–4, 82–3, 93–104, 124–5, 166–8
 concepts 29–34, 80–104, 120, 124–5, 138–9, 166–8, 173
 DCF steps 29–30, 92–104, 120, 124–5, 166–8
 real options 138–9
 VCs 173
discounted cash flow analysis (DCF) 4, 11–12, 27–37, 69–70, 80, 92–104, 119–39, 162–8
 concepts 4, 11–12, 27–37, 69–70, 80, 92–104, 119–39, 162–8
 construction methods 28–37, 92–101, 162–8
 critique 92–6, 119, 166–8
 decision trees 119–39
 definition 27
 discount rates 29–30, 92–104, 120, 124–5, 138–9, 166–8
 early-stage biotechnology companies 162–8
 EBIT DCF of products 97–104
 FCFE DCF model 29–37
 FCFF DCF model 29–37, 92–104
 forecasts 28–30, 92–101
 pitfalls 69, 92–3, 119
 steps 29–37, 92–101, 162–8
 terminal values 29–30, 34–7, 93–104, 171–3
 three-stage DCF model 36–7
discounted stocks 142–3, 168
discounted terminal values, concepts 171–2
discovery industry, concepts 5–6, 39, 40–4
diseases, probabilities of success/attrition 51–5, 106
distribution characteristics, ADMET 44–7
diversification 33–7
dividends
 concepts 15–17, 20–2, 28–9
 definition 15
DNA 5, 143
dosage ranges 55–6, 78–9, 104–5
double-blind studies, clinical-trials 49–50, 58
Dow Chemicals Company 103
Drakeman, Lisa 158–9
drug abuse 145
drug assets, concepts 73–118, 160
drug development 1–10, 12, 39–67, 73–4, 106–7, 126–39
 see also clinical-trials; R&D
 ADMET characteristics 44–7, 54–6
 attrition rates 51–4, 74, 106
 commercialization timelines 46, 47, 66, 125–6, 153
 concepts 1–10, 39–67, 106–7
 costs 40–4, 48, 55–6, 59, 66, 93
 decision trees 4, 8–9, 69, 119–39
 drug discovery 39, 40–7, 121–39, 145–53
 hurdles 3, 4, 8–10, 39, 41–2, 51–4, 92–3, 141, 154–5
 life cycles 1–2, 9–10, 42–4, 152–3
 opportunities and risks 7–8, 11–12, 39–40, 141–3
 phase 1 trials 42, 51–4, 54–5, 66, 73–4, 76, 86–92, 121–39, 155, 169–73
 phase 2 trials 42, 51–4, 55, 57–9, 66, 73–4, 76–7, 86–92, 108, 121–39, 155–6, 169–73
 phase 3 trials 42, 51–4, 55–6, 57–9, 60–3, 64–5, 73–4, 76, 86–92, 106–7, 121–39, 160, 169–73
 post-marketing surveillance studies (phase 4 trials) 42–4, 56, 65–6, 122
 preclinical development 42–7, 73–4, 86–92, 121–39
 probabilities of success/attrition 51–5, 74, 93, 106, 122–39
 product pipeline assessments 4, 46, 66, 69–70, 73–92, 106, 146–7, 155–6, 167–8
 real options 4, 69, 97, 119–20, 126–39, 147
 regulations 3, 4, 8–10, 39, 41–3, 47, 48, 56, 59–66, 143–4, 146–53
 risk 2–3, 7–10, 29, 32–7, 51–4, 60–3, 141–3
 routes of drug administration 46–7, 54, 104–5
 safety issues 41–7, 49–50, 59–67, 146–7
 stages' overview 42–4
 statistics 40–4, 143–59
 success rates 51–4, 93, 122–39
 technical hurdles 3, 8, 39, 41–2, 92–3, 141
 timelines 40–4, 47, 53, 65–6, 74–5, 121–39
drug discovery
 concepts 39, 40–7, 121–39, 145–53
 costs 40–4
 timelines 40, 44, 121–39
drug labels, concepts 62, 64–5
drugs 1–10, 19, 30, 39–67, 76–7, 118, 132–9, 142–3, 157–8, 169–70
 see also medicines; product...
 ADMET characteristics 44–7, 54–6
 bioavailability 46
 blockbuster drugs 76–83, 106, 118, 160
 exclusive marketing rights 43–4, 62
 generic drugs 44, 62–3, 157–8
 half life 45
 patents 3–4, 19, 30, 43–4, 76–7, 118, 132–9, 142–3, 157–8, 169–70
 routes of drug administration 46–7, 104–5
 side effects 44–6, 49–67, 104–5

- drugs (*Continued*)
 statistics 7, 40–4, 70–1, 141–59, 162–5
 uncertainty factors 2–3, 28–9
 volume of distribution 45
DTC *see* Direct To Consumer
due diligence 72–3
dynamic programming 127–30
- early-stage biotechnology companies 4, 5–6,
 11–12, 15, 33–4, 70–1, 99–101, 143–4,
 161–73
 see also private companies
 comparables valuation method 162, 168–70
 DCF valuation method 162–8
 failure rates 173
 sources of finance 161–2
 valuation 161–73
 VCs 1, 4, 12, 72, 148–53, 161–73
- Earnings Before Interest, Taxes, Depreciation and
 Amortization (EBITDA)
 concepts 6, 14–17, 25–6, 35, 99–105
 definition 14
 EV/EBITDA multiple 26, 101–5
 income statement multiples 25–6, 99–105
- Earnings Before Interest and Taxes (EBIT) 14,
 15–17, 25–6, 30, 35, 97–105
 concepts 14, 15–17, 25–6, 97–105
 DCF of products 97–104
 definition 15
 income statement multiples 25–6, 99–105
- earnings per share (EPS)
 concepts 14, 16–17, 22–6, 80–1, 147
 definition 16
 income statement multiples 22–5
 P/E ratios 25, 75–86, 88–92
- EBIT *see* Earnings Before Interest and Taxes
EBITDA *see* Earnings Before Interest, Taxes,
 Depreciation and Amortization
- economic models, valuation 27
- Eli Lilly 143
- EMEA *see* European Medicines Agency
- Encysive 61–2
- ENPV *see* expected NPV
- enterprise value (EV)
 concepts 6, 26, 29, 30, 101–3
 definition 26
- EPO 118
- Epogen 118
- EPS *see* earnings per share
- equation, balance sheets 17, 20
- equities
 see also shareholders' equity
 contingent claims on shares 16
 convertible securities 11, 16–17
 discounted stocks 142–3, 168
 VCs 161–2, 170–3
- equity finance
 concepts 11–12, 22, 26–7, 29–37, 92–4, 124–5,
 155, 161–2
 FCFE DCF model 29–37
 WACC 30–4, 36–7, 92–4, 124–5, 166–8
 equity risk premiums, concepts 34–7, 71, 125,
 166–8
- Erbitux 154
- Ernst & Young 144
- Erythropoietin 157
- Euronext 2
- Europe
 biotechnology statistics 7
 centralized procedures 63–4
 clinical-trials 48, 49, 57, 63–4
 CPMP 63–4
 EMEA 48, 60–1, 63–4, 118, 154, 157
 MRP 64
 patents 43
 pricing issues 64, 78
 public companies 143
 regulations 43, 48, 49, 57, 60–1, 63–4, 118,
 154, 157
 European Commission 63–4
 European Medicines Agency (EMA) 48, 60–1,
 63–4, 118, 154, 157
 European options 128
 EV *see* enterprise value
 EV/EBITDA multiple 26, 101–5
 Excel spreadsheets 82–3, 90
- excluded information
 effects 73–4
 press releases 56–9
- exclusive marketing rights 43–4, 62
- excretion characteristics, ADMET 44–7
- exits, VCs 161–2, 171–3
- expected NPV (ENPV) 92–104, 123–39
- expected rate of return 30–4, 94–5
- expenses
 see also costs; operating expenses
 income statements 12–17
- experience 2–4, 128–9, 145–6, 154–5, 160
- explicit forecasting periods 29–30
- failure rates, early-stage biotechnology
 companies 173
- fair value 71
- FCFE *see* free cash flow to equity
- FCFF *see* free cash flow to the firm
- FDA *see* Food and Drug Administration
- financial markets *see* markets
- financial options 16–17, 119–20, 126–39
 see also real...
- financial statements 2, 11–37, 71–4
 see also balance sheets; cash flow statements;
 income statements

- concepts 12–37, 71–4
- standards 13, 14, 101
- types 12–13
- financing activities, cash flow statement sections 21–2, 24
- financing windows, concepts 155
- FIPCOs *see* fully integrated pharmaceutical companies
- firm value *see* enterprise value
- first pass metabolism 47
- first-to-market advantages 8
- fiscal year, definition 13
- fixed assets
 - see also* assets
 - concepts 18–20, 21–2, 23–4
 - definition 19
- follow-on financing 147–9, 157
- Food and Drug Administration (FDA) 44, 48, 56, 58, 60–3, 65–7, 117–18, 146–7, 154, 156, 157–9
 - see also* US
 - biosimilar compounds 117–18
 - critique 146–7
- forecasts 28–30, 78–83
 - DCF construction 28–30, 92–101
 - explicit forecasting periods 29–30
- Fraxiparine 76
- free cash flow (FCF)
 - concepts 22, 29–37, 92–104
 - definition 22
- free cash flow to equity (FCFE), concepts 29–37
- free cash flow to the firm (FCFF)
 - concepts 29–37, 92–104
 - critique 36–7
- ‘free money’ 19
- FTSE100 94
- fully integrated pharmaceutical companies (FIPCOs) 147, 153
- future value (FV), definition 27–8
- G-CSF 157
- GAAP *see* Generally Accepted Accounting Principles
- GDP proportions, investments 145
- gearing 25, 30
- Genentech Inc. 5, 86, 103, 143–5
- general/administrative operating expenses, concepts 13–17
- Generally Accepted Accounting Principles (GAAP) 13, 14, 101
- generic drugs 44, 62–3, 157–8
- Genmab 94, 158–9
- Genzyme Corp. 103
- Gilead 147–8
- gilts 33–4
- Glaxo 64, 76, 94, 100–4
- global biotechnology statistics 7
- Global Settlement of April 2003 1–2
- glossary 1, 175–88
- going concerns 27
- Good Clinical Practice, clinical-trials 48, 50
- goodwill, definition 19
- GPC Biotech 58
- GPs 8
- GRA 108
- graphical aspects of decision trees 120–1
- gross profit
 - concepts 13–17, 23
 - definition 13–14
- growth hormones 118, 143–4, 157
- growth in perpetuity terminal values, concepts 35–6
- GSK 158–9
- half life, definition 45
- harmonization critique, regulations 59–60, 63–4
- head trauma 53
- health, warnings (black boxes) 62, 65
- healthcare investments
 - see also* biotechnology; investors
 - types 141–3
- high blood pressure 53, 54, 61–2, 77–8
- historic cost method, valuation 20
- historical aspects, biotechnology 5–7, 143–59
- history of the firm, data collation 72–3
- HIV/AIDS 54, 65, 145
- human genome 3, 7, 70, 143–5, 147–8, 153
- human insulin 118, 143, 157
- HuMax-CD20 158–9
- Humira 67
- Humulin 143
- hybrid companies 153
- hypertension *see* high blood pressure
- Ibbotson 33
- ICH *see* International Committee on Harmonization
- ‘if converted’ calculation method, diluted EPS 16–17
- IFRS *see* International Financial Reporting Standards
- Imclone 154
- impairment of goodwill 19
- implicit values 170–1
- in-licensing trends 146–7, 156
- income statements
 - balance sheets 21, 23
 - common size analysis 15–16
 - components 13–15
 - concepts 11–17, 21, 22–6
 - definition 12, 13

- income statements (*Continued*)
 layout example 13–14, 23
 multiples 11, 22–6, 27, 35–6, 99–104, 147
 relative valuation metrics 22–6
INDs *see* Investigational New Drug applications
industry newsletters 2
 see also biotechnology...
- inflation 95
- information sources 2–3, 4, 39–40, 41–2, 56–9,
 71–83, 145–53, 158–9
- infusion injections 47
- inhalation administration 47, 54
- initial public offerings (IPOs) 70–1, 143–4,
 148–52, 158–9, 162, 168–70, 172
- institutional investors 2–3
 see also investors
- insulin 118, 143, 157
- intangible assets
 see also amortization; patents
 concepts 14–17, 19, 20, 21–2, 70–1
 definition 14–15, 19
 intellectual capital 20, 43, 132–3, 143
- integrity, management quality 154–5
- intellectual capital 20, 43, 132–3, 143
- intellectual property rights 43–4, 132–3, 143
 see also patents
- intent-to-treat analysis, clinical-trials 51, 58
- interest expenses
 concepts 14–17, 22, 23, 29
 definition 15
- interest rates 2, 27–37
- interferon 118
- interim study analysis, clinical-trials 50–1
- internal rate of return (IRR) 173
- International Committee on Harmonization (ICH)
 48, 50
- International Financial Reporting Standards
 (IFRS) 13
- intramuscular administration 47, 54
- intravenous injections 46, 47, 54, 67
- introduction 1–10
- inventory
 concepts 18–19, 21–4
 definition 19
- Investigational New Drug applications (INDs) 48,
 62
- investment banks
 see also sell-side analysis
 critique 1–2
- investments
 see also healthcare...
 affiliates 19
 cash flow statement sections 21–2, 24
 cycles 2–3, 142, 144, 145–52
 early-stage biotechnology companies 161–73
 follow-on financing 147–9, 157
- GDP proportions 145
 guidelines 56–9, 61–2, 66, 73–4, 141–60
 IPOs 70–1, 143–4, 148–52, 158–9, 162,
 168–70, 172
 lessons 141–2, 160
 stock selections 145, 149–52, 160
 VCs 1, 4, 12, 72, 148–53, 161–73
- investors 1, 4, 6–8, 12, 39, 45–7, 56–9, 61–2,
 70–5, 141–60, 161–73
 see also institutional...
 boom of 2000 2–3, 144, 147–8, 156
 clinical-trials analysis guidelines 56–9, 61–2,
 66, 73–4, 141–60
 healthcare investment types 141–3
 informed investors 39, 45–7, 56–9, 61–2, 66,
 70, 71–5, 141–60
 lessons 141–2, 160
 preclinical development 45–6, 73–4
 statistics 7, 40–4, 141–59
 stock selections 145, 149–52, 160
 successful investors 4, 9–10, 37, 39, 56–9,
 141–60
 VCs 1, 4, 12, 72, 148–53, 161–73
- IPOs *see* initial public offerings
- IRR *see* internal rate of return
- Japan
 patents 43
 regulations 43, 59, 64
- Johnson and Johnson (J&J) 49, 160
- junior debt, definition 31
- Kennedy, Edward 117
- kidneys 45
- Kohler, Georges 5
- Labopharm 160
- late-stage products 146–7, 160
- launch dates 74–5, 82–92, 134–5
- lawsuits 72–3
- learning curves 2–3
- lessons for investors 141–2, 160
- liabilities
 see also current...
 balance sheets 13, 17–24
 definition 19
- licensing opportunities 1–2, 11–12, 15–17, 146–8
- life cycles 1–2, 9–10, 42–4, 70–1, 152–3
- life-saving therapy exemptions, regulations 56, 65
- Lilly 44
- liquidation values, concepts 26–7
- liver 45, 47
- lognormal distributions 128–9
- London Stock Exchange (LSE) 2, 143, 154
- long-term assets, concepts 18–20, 21–2
- long-term liabilities, concepts 18, 20, 23–4

- losses
 biotechnology statistics 7, 70–1, 76–7, 79–80, 141–3, 144–5, 149–52, 158–9
 most biotech companies 15, 70–1, 79–80, 141–2, 144–5, 149–52
LSE *see* London Stock Exchange
Lundbeck A/S 100–4
- M&As *see* mergers and acquisitions
M6G 57, 106–8
malignant melanoma 77–8
management accounts 4
management quality
 discounts 12
 experience 2–4, 128–9, 145–6, 154–5, 160
 integrity 154–5
 valuation determinants 11–12, 69–70, 97, 128–9, 145–6, 154–5, 160
market models 104–15
market risk, concepts 32–4
market share 8–10, 77–82
 see also commercial risk
market values
 comparable company analysis 4, 11, 15–17, 22–6, 71–2, 99–104
 shareholders' equity contrasts 20
marketable securities, concepts 18–20
marketing
 drug labels 64–5
 rights 43–4, 62
markets 2–3, 8–10, 77–82, 92–3, 132–3, 152–3, 156–9
 commercial risk 8–10, 92–3, 132–3, 156–9
 life cycles 9–10, 152–3
 quick market models 77–82
mean 32–3
Medicaid 157
Medicare 157
medicines 5–10, 39–67
 see also drug...; product...
MedImmune 147–8
MEDLINE 40
Merck 57–8, 83–4, 94, 101–5, 136
mergers and acquisitions (M&As) 143–5, 146–7, 151–3, 160, 162
 see also partnerships
metabolism characteristics, ADMET 44–7
Michael J. Fox foundation 161
Milstein, Cesar 5
minority interests 26
MMI 94
monoclonal antibodies 5–6, 147
Monte Carlo 136–7
morphine 57, 106–7
MRP *see* Mutual Recognition Procedure
MS *see* multiple sclerosis
- MSCI World index 94
multiple calculations, terminal values 97
multiple derived terminal values, concepts 35
multiple sclerosis (MS) 108–15, 145
multiple techniques, valuation 11–12, 22–7, 106
multiple valuation techniques, benefits 11–12
multiples
 balance sheets 26–8, 99–104
 comparable company analysis 99–104
 income statements 11, 22–6, 27, 35–6, 99–104, 147
Mutual Recognition Procedure (MRP) 64
mutually exclusive outcomes, chance nodes 121–3
- NASDAQ 2, 142–3
Nasdaq Biotechnology Index (NBI) 94, 142–3
National Institute for Clinical Excellence (NICE) 64
NBI *see* Nasdaq Biotechnology Index
NCEs *see* new chemical entities
NDAs *see* New Drug Applications
net fixed assets, definition 19
net income
 biotechnology statistics 7
 concepts 7, 14, 16–17, 21–4
 definition 14, 16
net present value (NPV) 4, 11–12, 27–8, 36, 69–70, 74–92, 101–3, 106–7, 119, 122–39, 162–8
 additive aspects 101–3
 concepts 4, 11–12, 27–8, 36, 74–92, 101–3, 106–7, 119, 162–8
 definition 27–8
 formula 27
 news impacts 106–7
 pNPV 4, 69–70, 74–92, 106–7, 139
 sensitivity analysis 86–92, 105
net working capital, definition 30, 37
Neupogen (Filgrastim) 157
neuropathic pain 77–8
new chemical entities (NCEs) 60–3
New Drug Applications (NDAs) 58–66, 134–9
Newron 57–8
news flows 2–3, 7–8, 41–2, 56–9, 61–2, 74–5, 106–7, 142–3, 145–53, 158–9
NICE *see* National Institute for Clinical Excellence
node types, decision trees 120–3
non-inferiority trials 55–6
 see also phase 3 trials
non-valuation metrics 2–4, 11
NoSH *see* number of shares outstanding
Novartis 94, 157
Novo Nordisk A/S 100–4
NPV *see* net present value
number of shares outstanding (NoSH) 80–6

- obesity 145–6
objective/subjective assessments, analysis 2–3,
11, 28–30, 69–70, 119–20, 141–60
ODAC 58
Omnitrope 157
Ondine Biopharma 94
operating businesses, valuation determinants
11–12
operating cash flow
concepts 14–17, 21–2, 24
EBITDA links 14–15
operating expenses
see also expenses
common size analysis 15–17
concepts 13–17, 23–4
definition 13–14
operating profit *see* Earnings Before Interest and
Taxes
opportunities, drug development 7–8, 11–12,
39–40, 141–3
opportunity costs 30–1, 40–1
options 16–17, 119–20, 126–39
see also real...
oral administration 46, 47, 54
orphan drug status 43–4, 48
Orplatna 58–9
osteoarthritis 77–8
out-licensing opportunities 1–2, 11–12, 15–16,
146–8
overview of the book 3–10

P/E ratios *see* price/earnings ratios
PAH 61–2
Parkinson's disease 54, 161
partnerships 7–10, 15–16, 57–8, 74–5, 83–6,
143–60
see also mergers and acquisitions
benefits 74, 143, 147, 156–60
commercial risk 8–10
historical background 143–4
PAT *see* profit after tax
patents 3–4, 19, 30, 43–4, 76–7, 118, 132–9,
142–3, 157–8, 169–70
see also intangible assets; intellectual property
rights
timelines 43, 142
patient-based market models 104–15
PBT *see* profit before tax
PCPI *see* Private Company Price Index
PDUFA *see* Prescription Drug User Fee Act
peak sales estimates, pNPV 75–92, 104–15
PEG *see* price/earnings to growth ratios
people 3–4, 20, 154–5, 160
see also intellectual...; management...
'per protocol' analysis, clinical-trials 51, 58
Performance & Life Sciences Chemicals
102–3

perpetuities
growth in perpetuity terminal values 35–6
terminal value calculations 97
pharmaceutical industry 1, 4, 6–7, 39–67, 83–6,
141–60
see also companies
biotechnology contrasts 6–7
FIPCOs 153
valuation 6–7
pharmaceutical P/E ratio 82–6
see also price/earnings ratio...
Pharmaceutical Research and Manufacturers of
America (PhRMA) 40–2
pharmacodynamics, definition 45
pharmacokinetics
concepts 45–7
definition 45
phase 1 trials 42, 51–4, 54–5, 66, 73–4, 76,
86–92, 121–39, 155, 169–73
phase 2 trials 42, 51–4, 55, 57–9, 66, 73–4, 76–7,
86–92, 108, 121–39, 155–6, 169–73
phase 3 trials 42, 51–4, 55–6, 57–9, 60–3, 64–5,
73–4, 76, 86–92, 106–7, 121–39, 160,
169–73
phase 4 trials *see* post-marketing surveillance
studies
PhRMA *see* Pharmaceutical Research and
Manufacturers of America
physical inactivity 145
pipeline assessments 4, 46, 66, 69–70, 73–92,
106, 146–7, 155–6, 167–8
pivotal trials *see* phase 3 trials
placebo controls, clinical-trials 49–50, 55
plant, property and equipment (PPE) *see* fixed
assets
platform technology companies 7–8
Plethora Solutions 94, 108
PMS *see* post-marketing surveillance studies
(phase 4 trials)
pNPV *see* probability weighted NPV
post financing VC valuations 171–3
post-marketing surveillance studies (phase 4
trials) 42–4, 56, 65–6, 122
post-operative nausea and vomiting (PONV) 57,
106–8
pre-money VC valuations 171–3
preclinical development
ADMET characteristics 44–7
concepts 42–7, 73–4, 86–92, 121–39
costs 45
investors 45–6, 73–4
routes of drug administration 46–7
preferred stock
concepts 17, 20, 26
definition 20
prepaid expenses 18, 23–4
Prescription Drug User Fee Act (PDUFA) 58, 160

- prescription-based market models 104–15
present value (PV)
 see also net present value
 definition 28
presentations 7–8, 154–5
press releases 2, 41–2, 56–9, 61–2, 74–5, 106–7, 158–9
‘Prevention, Randomized, Double-Blind, Placebo Control’ design summary, clinical-trials 49–50
price targets 2–3, 9
price/book ratios, concepts 26–7
price/earnings ratios (P/E...)
 concepts 25, 35, 75–86, 88–92, 147, 168–9
 definition 25
 income statement multiples 25, 147
 pharmaceutical P/E ratio 82–6
price/earnings to growth ratios (PEG), concepts 25
price/sales ratio, income statement multiples 25–6
pricing issues
 Europe 64, 78
 US 78
private companies 4, 12, 37, 143–5, 149–52, 161–73
 see also companies; early-stage...
 biotechnology statistics 7, 144–5, 162–5
 comparables valuation method 162, 168–70
 DCF valuation method 162–8
 PCPI 168–9
 public companies 162, 168
 valuation 37, 161–73
 VCs 1, 4, 12, 72, 148–53, 161–73
Private Company Price Index (PCPI) 168–9
probabilities, decision trees 119–39
probabilities of success/attrition, drug development 51–5, 74, 93, 106, 122–39
probability weighted NPV (pNPV)
 assumptions 80–3
 calculation method 75–86
 concepts 4, 69–70, 74–92, 106–7, 139
Procrit 118
product pipeline assessments 4, 46, 66, 69–70, 73–92, 106, 146–7, 155–6, 167–8
product-based biotechnology investments 1–2, 7–10
productivity drives, R&D 147
profit after tax (PAT), concepts 25–6
profit before tax (PBT), concepts 25–6
profit and loss accounts (P&L) *see* income statements
profits, biotechnology statistics 7, 70–1, 76–7, 86–7, 141–3, 144–5, 149–52, 158–9
proof of concept studies *see* phase 2 trials
proprietary technology 19
 see also intangible assets
prostate cancer 58–9
Protropin 143–4
Prozac (fluoxetine) 44, 63
PSD597 108
public companies 4, 12, 143–59, 162, 168
 see also companies
 biotechnology statistics 7, 141–59
 historical background 143
 IPOs 70–1, 143–4, 148–52, 158–9, 162, 168–70, 172
 private companies 162, 168
PubMed 77–8
Purdue Pharma 160
quick market models 77–82
R&D 6–7, 11–12, 13–17, 39–67, 74, 99–101, 127, 143–59, 169–70
 see also drug development
 biotechnology statistics 7, 40–4, 143–59
 budget allocations 42–3, 144
 common size analysis 15–16
 concepts 7, 11–12, 39–67, 74, 147–8, 169–70
 costs 40–4, 55, 169–70
 operating expenses 13–17
 opportunities 11–12, 39–40
 productivity drives 147
 statistics 7, 40–4, 143–59
 tax expenses 41
Rafinamide 57–8
randomized clinical-trials
 see also clinical-trials
 concepts 49–50, 55
Rapporteurs 63–4
real options
 see also decision trees
 binomial lattices 119–20, 127–8, 129–39
 Black-Scholes equation 119–20, 127–8, 129–30, 134–9
 categories 129
 concepts 4, 69, 97, 119–20, 126–39, 147
 definition 119–20, 126–7
 discount rates 138–9
 financial options 126–7
 in-licensing trends 147
 input variables estimates 138–9
 uses 119–20
 variables 127–8
Rebif 112–16
recombining binomial lattices 129–39
rectal administration 47, 54
references 189–92
regulations
 clinical-trials 41–3, 47, 48, 49–50, 56, 59–66, 146–53
 concepts 3, 4, 8–10, 39, 41–3, 47, 48, 56, 59–66, 92–3, 142–4, 146–53, 154
 critique 59–60

- regulations (*Continued*)
 drug development 3, 4, 8–10, 39, 41–3, 47, 48, 56, 59–66, 143–4, 146–53
 drug labels 62, 64–5
 Europe 43, 48, 49, 57, 60–1, 63–4, 118, 154, 157
 harmonization critique 59–60, 63–4
 Japan 43, 59, 64
 life-saving therapy exemptions 56, 65
 UK 48, 64, 154
 US 43, 48, 49, 58, 59–63, 64–5, 66–7, 116–18, 143–4, 154, 157–9
 regulatory filings, information sources 71–2
 relative valuation
 see also comparable company analysis
 concepts 22–6, 69, 71, 99–104, 168–70
 Relenza 64
 Remicade 66–7
 replicating portfolios, Black-Scholes equation 127–8
 retained earnings
 concepts 15–17, 18, 20, 23–4
 definition 20
 retention ratios 171–3
 returns 29, 30–4, 70–1, 93–104, 139, 141–3, 144–5, 146–7, 149–52, 158–9, 161–2, 166–8, 171–3
 see also profit...
 distributions 139
 expected rate of return 30–4, 94–5
 risk 29, 32–4, 93–104, 141–3, 146–7, 161–2, 166–8, 171–3
 revenues 7, 12–17, 75–92, 147–52
 biotechnology statistics 7, 147–52
 income statements 11–17
 recognition considerations 15–17
 rheumatoid arthritis 134–5
 @Risk 136–7
 risk 2–3, 7–10, 29, 32–7, 51–4, 60–1, 92–104, 125–6, 141–3, 146–7, 161–2, 166–8, 171–3
 see also uncertainty
 appetites 141–3, 146–7
 clinical-trials 49–50, 51–4, 60–1
 diversification 33–7
 returns 29, 32–4, 93–104, 141–3, 146–7, 161–2, 166–8, 171–3
 types 7–10, 32–3, 92–3, 125–6, 132–3, 153
 risk adjusted net present value (rNPV) 92–3
 risk-free interest rates 33–7, 93–104, 120, 124–5, 127–39, 166–8
 risk-neutral probabilities 131–9
 risky health behaviours 145–6
 rNPV *see* risk adjusted net present value
 Roche 94
 routes of drug administration, concepts 46–7, 54, 104–5
 royalties
 concepts 14–17, 74, 80–6, 97–9
 net royalties 86
 S&P500 142–3
 SABs *see* Scientific Advisory Boards
 safety issues
 clinical-trials 49–50, 51–4, 60–6, 146–7
 drug development 41–7, 49–50, 59–67, 146–7
 post-marketing surveillance studies (phase 4 trials) 42–4, 59–67, 122
 sales 7, 12–17, 75–92, 104–15
 see also revenues
 peak sales estimates 75–92, 104–15
 sales forces 46
 Sanofi 94, 100–4
 scandals 154–5
 scenario analysis, decision trees 125–6
 Scientific Advisory Boards (SABs) 154–5
 SEC *see* Securities and Exchange Commission
 sector evolution, biotechnology 143–59
 secured debt 31–2
 Securities and Exchange Commission (SEC) 71, 154
 selection of subjects, clinical-trials 49
 sell-side analysis 1–4, 11–12, 73–4
 see also investment banks
 critique 1–2
 roles 1–2
 subjective/objective assessments 2–3, 11
 sellers 1–10
 selling operating expenses, concepts 13–17
 senior debt, definition 31
 sensitivity analysis, concepts 11–12, 86–92, 105
 Serono 83–7
 shareholder value 126–7, 141, 154–5
 shareholders' equity
 see also equities
 balance sheets 17–18, 20
 definition 20
 market value contrasts 20
 Shire Pharmaceuticals 61, 94, 97–9, 100–4
 short-term debt
 concepts 18, 19–21
 definition 19
 side effects
 concepts 44–6, 49–67, 104–5
 drug labels 62, 64–5
 Sigma Aldrich Corp. 103
 smoking 145
 sNDAs *see* supplemental new drug applications
 Solvay 103
 SPARC trial 58
 SPCs *see* Supplementary Protection Certificates
 specific risk
 concepts 32–4, 125–6
 definition 32–3

- Spiriva 76–7
staged capital infusions, VCs 161–2
stages' overview, drug development 42–4
standard deviation 32–3, 130–9
standards
 clinical-trials 48
 financial statements 13, 14, 101
 GAAP 13, 14, 101
'star' scientists 20
start-ups, background 4, 5–6, 11–12, 15, 33–4,
 70–1, 99–101, 143–4, 152–3
Stevenson-Wylder Act 143
stock options 16–17
stock selections 145, 149–52, 160
strike prices, options 127–39
study analysis, clinical-trials 48, 50–1, 56–59
study conduct, clinical-trials 48, 50
study design, clinical-trials 48, 49–50
study endpoints, clinical-trials 50
study objective, clinical-trials 48–9, 56, 58
study report, clinical-trials 48, 51, 56–9,
 60–3
subcutaneous administration 47, 54
subjective/objective assessments, analysis 2–3,
 11, 28–30, 69–70, 119–20, 141–60
sublingual administration 47
success rates, clinical-trials 51–4, 93, 122–39
successful investors 4, 9–10, 37, 39, 56–9,
 141–60
Sulfonamide 57–8
supplemental new drug applications (sNDAs)
 62–3
Supplementary Protection Certificates (SPCs)
 43–4
surrogate markers 59
Swanson, Bob 5
SWX 2
syndicated VC investments 161–2
systematic risk *see* market risk
- target capital structure, definition 31
target product profiles (TPPs) 74–5, 104–15, 156
tax expenses
 concepts 14–17, 20, 23–4, 41
 definition 15
 R&D 41
technical hurdles, drug development 3, 8–10, 39,
 41–2, 92–3, 141
technical risk 7–10, 92–3, 125–6, 132–3, 153
 see also clinical-trials; regulations
 concepts 7–10, 92–3, 132–3, 153
 decision trees 8–9, 125–6
 definition 8
terminal values, concepts 29–30, 34–7, 93–104,
 171–3
termination nodes, concepts 120–3
Teva 157
- Thelin 61–2
therapeutic indices 45
therapeutic proteins 147
three-stage DCF model 96–7
thrombosis 54, 77
'time is money' 43
time to expiration, options 127–39
time value of money
 see also discounted cash flow...
 concepts 27
timelines
 clinical-trials 40, 41–4, 53, 65–6, 121–39
 commercialization timelines 46, 47, 66, 125–6,
 153
 decision trees 120–3
 drug development 40–4, 47, 53, 65–6, 74–5,
 121–39
 drug discovery 40, 44, 121–39
 patents 43, 142
top-down approaches, quick market models
 77–82
topical administration 47, 54
Total Assets, concepts 18–19, 23–4
Total Current Assets, concepts 18–19, 23–4
Total Liabilities and Shareholders' Equity,
 concepts 18, 20, 23–4
toxicology characteristics, ADMET 45–7, 54–5
TPPs *see* target product profiles
trademarks 19
 see also intangible assets
traditional valuation methods 11–37, 105–6
tramadol 160
transdermal administration 47, 54
transparent valuation methodologies 3–4
treasury stock 16–17, 20, 136–7
TSX 2
Tufts Center for the Study of Drug Development
 40
Tygacil 49
Tysabri 60–1
- UCB 66–7, 94
UK
 clinical-trials 48
 IPOs 149–52, 158–9
 LSE 2, 143, 154
 public companies 143, 149–52
 regulations 48, 64, 154
uncertainty 2–3, 28–9, 92–3, 119–39
 see also risk
underlying assets
 options 127–39
 volatility estimations 135–7, 139
underperformance trends, companies 141–3,
 149–52
unsecured debt 31–2
unsystematic risk *see* specific risk

US

- Access to Life Saving Medicines Act 157–8
 - advisory committees 60–3, 146–7
 - approvable/approved issues 61–2, 65, 126, 146, 154, 157
 - Bayh-Dole Act 143
 - biosimilar compounds 106, 116–18
 - biotechnology statistics 7, 40–4, 142–59
 - clinical-trials 48, 49, 58, 60–3, 145–53
 - Diamond v. Chakrabarty* 143
 - disease models 108–15
 - drug labels 61, 62, 64–5
 - FDA 44, 48, 56, 58, 60–3, 65–7, 117–18, 146–7, 154, 156, 157–9
 - IPOs 149–52
 - MS 108–15
 - patents 43
 - PDUFA 58, 160
 - pricing issues 78
 - public companies 143–4, 149–52
 - regulations 43, 48, 49, 58, 59–63, 64–5, 66–7, 116–18, 143–4, 154, 157–9
 - Stevenson-Wydler Act 143
- Valtropin 157
- valuation 1–10, 11–37, 69–118, 119–39, 143–4, 171–3
- accounting models 27
 - ‘art’ factors 2–4, 11, 37, 69–70, 119
 - background 1–10, 11, 22–7, 69–118
 - balance sheet multiples 26–7, 99–104
 - comparable company analysis 4, 11, 15–17, 22–6, 71–2, 99–104, 162, 168–70
 - concepts 2–10, 11–37, 69–118
 - consistency benefits 3–4
 - DCF 4, 11–12, 27–37, 69–70, 80, 92–104, 119–39, 162–8
 - early-stage biotechnology companies 4, 5–6, 11–12, 15, 33–4, 70–1, 99–101, 143–4, 161–73
 - economic models 27
 - free cash flow uses 22
 - historic cost method 20
 - income statements multiples 11, 22–6, 27, 35–6, 99–104
 - IPOs 168–70
 - management quality 11–12, 69–70, 97, 128–9, 145–6, 154–5, 160
 - Merck example 101–5
 - multiple techniques 11–12, 22–7, 106
 - non-valuation metrics 2–4, 11
 - NPV 4, 11–12, 27–8, 36, 69–70, 74–92, 101–3, 106–7, 119, 122–39, 162–8
 - options 126–39
 - P/E ratios 25, 35, 75–86, 88–92, 147, 168–9
 - pharma/biotechnology contrasts 6–7
 - pNPV 4, 69–70, 74–92, 106–7, 139
 - post financing VC valuations 171–3
 - pre-money VC valuations 171–3
 - private companies 37, 161–73
 - product pipeline assessments 4, 46, 66, 69–70, 73–92, 106, 146–7, 155–6, 167–8
 - real options 4, 69, 97, 119–20, 126–39, 147
 - traditional methods 11–37, 105–6
 - transparency benefits 3–4
 - variety of metrics 3, 27, 69–70
 - VC method 170–3
- value 126–7, 141, 154–5
- variety of valuation metrics 3, 27, 69–70
- VCS *see* venture capitalists
- Vectura 94
- venture capitalists (VCs) 1, 4, 12, 72, 148–53, 161–73
- concepts 148–53, 161–73
 - definition 161
 - discount rates 173
 - equities 161–2, 170–3
 - exits 161–2, 171–3
 - post financing valuations 171–3
 - pre-money valuations 171–3
 - roles 161–2
 - statistics 148–53, 162–5
 - tools 161–2
 - valuation method 170–3
- volatility
- concepts 2–3, 41–2, 125, 127–39
 - underlying volatility estimates 135–7, 139
- volume of distribution, definition 45
- VYVANSE 61
- WACC *see* weighted average cost of capital
- warrants 16–17
- web resources
- clinical-trials 40
 - data collection 71–5
- weighted average cost of capital (WACC)
- concepts 30–4, 36–7, 92–4, 124–5, 166–8
 - definition 30–1
- ‘winner’s curse’ 149
- working capital 21–2, 30, 37
- YM Biosciences 94
- zero terminal values, concepts 35
- Zocor/Zetia 76–7
- Zyvox 49